We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
- Authors
Landman, Roland; Capitant, Catherine; Descamps, Diane; Chazallon, Corine; Peytavin, Gilles; Katlama, Christine; Pialoux, Gilles; Bentata, Michelle; Brun-Vézinet, Francoise; Aboulker, Jean-Pierre; Yéni, Patrick
- Abstract
Objectives We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients. Methods Thirty patients received fosamprenavir/atazanavir/ritonavir (Group 1) and 31 patients received saquinavir/atazanavir/ritonavir (Group 2). The primary endpoint for efficacy was the rate of early virological success, defined as plasma viral load Results At baseline, median (range) viral load was 4.8 log10 copies/mL (4.0–5.7) and the median CD4 cell count was 271/mm3 (197–740). Viral load was Conclusions Ritonavir-boosted dual protease inhibitor regimens targeting only one step of viral replication were insufficient to rapidly suppress plasma HIV RNA to
- Subjects
PROTEASE inhibitors; DRUG efficacy; ANTIRETROVIRAL agents; HIV-positive persons; DRUG tolerance; VIROLOGY; VIRAL load; REVERSE transcriptase
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2009, Vol 64, Issue 1, p118
- ISSN
0305-7453
- Publication type
Article